Targeting Pain Nerves Outside the Brain Could Make Cannabinoid Pain Drugs Practical
A review of peripherally restricted cannabinoids found that targeting cannabinoid receptors on pain-sensing nerves outside the brain could provide pain relief without psychoactive effects, tolerance, or dependence.
Quick Facts
What This Study Found
This review examined strategies to use cannabinoids for pain treatment while avoiding central nervous system effects. Cannabinoid receptors (CB1 and CB2) are abundant on peripheral pain-sensing nerves, and activating them locally can reduce pain signaling.
Several approaches were discussed: using cannabinoid compounds that cannot cross the blood-brain barrier, developing CB2-selective agonists (since CB2 is less prevalent in the brain), and local delivery of cannabinoids directly to painful tissues.
The review noted that peripheral cannabinoid approaches could be particularly beneficial for conditions with prominent peripheral mechanisms, such as diabetic neuropathy and chemotherapy-induced neuropathy, where peripheral nerve damage drives pain.
Key Numbers
23 states had legalized medical marijuana at the time; conditions highlighted: diabetic neuropathy, chemotherapy-induced neuropathy; strategies: blood-brain barrier exclusion, CB2 selectivity, local delivery
How They Did This
Narrative review of scientific evidence for peripheral cannabinoid system targeting, examining available literature on strategies to achieve pain relief without CNS effects.
Why This Research Matters
The main barriers to cannabinoid pain medication are psychoactive effects and dependence potential. If cannabinoids can be restricted to peripheral nerves, these barriers could be eliminated while retaining pain-relieving activity.
The Bigger Picture
The opioid crisis has created urgent demand for non-addictive pain medications. Peripherally restricted cannabinoids represent a promising class of analgesics that could fill this need without the abuse potential of opioids or centrally-acting cannabinoids.
What This Study Doesn't Tell Us
Most peripheral cannabinoid approaches were in preclinical stages. Blood-brain barrier exclusion is difficult to achieve perfectly. Some pain conditions involve central sensitization that peripheral approaches alone may not address.
Questions This Raises
- ?Can peripherally restricted cannabinoids provide sufficient pain relief for severe pain?
- ?Will local cannabinoid delivery be practical for chronic conditions?
- ?How do peripheral cannabinoid analgesics compare to existing pain medications?
Trust & Context
- Key Stat:
- Peripheral targeting avoids psychoactive effects, tolerance, and dependence
- Evidence Grade:
- Comprehensive review of a promising therapeutic strategy, though most evidence was preclinical at the time.
- Study Age:
- Published in 2015. Development of peripherally restricted cannabinoid analgesics has continued.
- Original Title:
- Peripherally Restricted Cannabinoids for the Treatment of Pain.
- Published In:
- Pharmacotherapy, 35(10), 917-25 (2015)
- Database ID:
- RTHC-01051
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can you get pain relief from cannabinoids without getting high?
This review described several strategies to achieve this: using cannabinoids that cannot enter the brain, targeting CB2 receptors instead of CB1, or delivering cannabinoids locally to painful tissues. These approaches showed promise in preclinical research.
Would these work for nerve pain?
The review highlighted diabetic neuropathy and chemotherapy-induced neuropathy as particularly suitable conditions because the pain originates from peripheral nerve damage, where cannabinoid receptors are abundant and locally targeted treatment could be effective.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01051APA
Romero-Sandoval, E Alfonso; Asbill, Scott; Paige, Candler A; Byrd-Glover, Kiara. (2015). Peripherally Restricted Cannabinoids for the Treatment of Pain.. Pharmacotherapy, 35(10), 917-25. https://doi.org/10.1002/phar.1642
MLA
Romero-Sandoval, E Alfonso, et al. "Peripherally Restricted Cannabinoids for the Treatment of Pain.." Pharmacotherapy, 2015. https://doi.org/10.1002/phar.1642
RethinkTHC
RethinkTHC Research Database. "Peripherally Restricted Cannabinoids for the Treatment of Pa..." RTHC-01051. Retrieved from https://rethinkthc.com/research/romero-sandoval-2015-peripherally-restricted-cannabinoids-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.